News

The top therapeutic advancements in myopia, diabetes, dry eye and more

A look at the biggest news and advancements in ophthalmology in 2024.

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet stripping only (DSO). Long-term outcomes show promising results, supporting DSO as a viable alternative to traditional donor-tissue-based keratoplasty procedures.

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 inhibitor therapy.

Options empower patients and providers to decrease treatment burden.

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual function in optic neuropathy patients. Clinical trials show promising results in visual field improvements, though further research is needed on long-term efficacy and quality of life.

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's Journal Club, highlighting a 77% success rate at 5 years and evolving techniques.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty discussions on ophthalmology research to enhance clinical practice and trainee education.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Did you miss any of our print issues this year? Don’t worry, they are still available online.

The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.

Enhancing durability and reducing treatment burden.

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

Our top 10 print stories highlight the core content concepts we explored this year

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

The report details the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025.

The publication is entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.”

Low-level light therapy for dry eye disease and chalazion